Metal salts and uses thereof
The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof.
1. An amorphous zinc salt of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid (Compound 1), wherein the zinc salt is a 2:1 (Compound 1:zinc) salt.
2. The zinc salt claim 1 having less than 1% mass loss up to decomposition as measured by thermal gravimetric analysis.
3. A pharmaceutical composition comprising the zinc salt of claim 1 and a pharmaceutically acceptable excipient.
4. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition comprises less than 1.5 weight % of sodium.
5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is substantially free of the 1:1 sodium salt of Compound 1.
6. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is in unit dosage form.
7. The zinc salt of claim 1 , wherein the zinc salt has a peak with increased intensity relative to the free acid at about 1590±10 cm −1 and a peak with reduced intensity relative to the free acid at about 1710±10 cm −1 as measured by Fourier-transform infrared spectroscopy (FTIR).